Item 8.01 Other Events.

Hana Biosciences, Inc. (the "Company") previously disclosed in a Current Report on Form 8-K filed on November 21, 2008, that it had received a written notice from the staff of The Nasdaq Stock Market ("Nasdaq") informing the Company that it did not comply with Nasdaq Marketplace Rule 4310(c)(3). That rule requires the Company maintain a minimum of $2,500,000 in stockholders' equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. Nasdaq's notice requested the Company to submit a plan to achieve and sustain compliance with Rule 4310(c), which the Company submitted on December 4, 2008.

By letter dated December 22, 2008, the Nasdaq staff notified the Company that it was granting the Company an extension of time to regain compliance with Rule 4310(c). Under the terms of the extension, the Company must furnish to the SEC and Nasdaq, on or before March 4, 2009, a publicly available report providing specified disclosures and affirmations, including a description of a completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. If the Company is unable to regain compliance by March 4, 2009, the Nasdaq staff may provide notice to the Company that its common stock is being delisted. At that time, the Company may appeal the staff's decision to a Nasdaq Listing Qualifications Panel.